Patent · US Active

Prevention and treatment of complement-associated eye conditions

US8007791B2 · kind B2 · utility

20Cited by

9References

13Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Philip E. Hass · Moss Beach, US
Yin Jianping · Foster City, US
Kenneth Katschke · Fairfield, US
Micah Steffek · San Francisco, US
Christian Wiesmann · Brisbane, US
Menno Van Lookeren Campagne · San Francisco, US

Key dates

Filing date	May 22, 2008
Grant date	Aug 30, 2011
Priority date	—
Expiry date	Aug 26, 2029

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S435/975
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.